세계의 엑소좀 기술 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Exosome Technologies Market is presumed to reach the market size of nearly USD 510.04 Million by 2032 from USD 66.42 Million in 2023 with a CAGR of 25.42% under the study period 2024-2032.

Exosome technologies focus on the utilization of exosomes, which are small extracellular vesicles released by cells that play an integral role in cell-to-cell communication. These vesicles carry proteins, lipids, and genetic material, influencing various physiological and pathological processes. It encompasses their isolation, characterization, and application in diagnostics and therapeutics. In diagnostics, exosomes can be biomarkers for cancer and neurodegenerative disorders. Therapeutics are explored for drug delivery and regenerative medicine, as they can deliver therapeutic molecules to specific target cells. Advances in these technologies hold promise for personalized medicine and novel treatment strategies.

MARKET DYNAMICS

The increasing interest in exosomes for their potential in diagnostics and therapeutics is driving the growth of the exosome technologies market. Exosomes, as natural carriers of biomolecules, offer a non-invasive means of disease detection and monitoring, which is particularly valuable in cancer diagnostics and other medical fields. Advancements in isolation and characterization techniques enhance the efficacy and reliability of exosome-based applications, further propelling market growth. The rising burden of chronic diseases and the need for effective treatment options also boost market growth. Furthermore, significant investments in research and development by biotech companies and research institutions are accelerating innovations and expanding the potential applications of exosome-based products. Regulatory approvals and support for clinical trials provide a conducive environment for the commercialization of exosome technologies. The increasing focus on personalized medicine, where exosome-based diagnostics and therapeutics can be tailored to individual patient profiles, is another factor driving market growth. Additionally, the potential of exosomes in drug delivery systems, due to their ability to transport therapeutic agents across biological barriers, garners significant attention and investment, contributing to the robust growth of the exosome technologies market. However, challenges in large-scale production, standardization of isolation techniques, and regulatory approval processes may hinder market growth in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Exosome Technologies. The growth and trends of Exosome Technologies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Exosome Technologies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Exosome Type

• Loaded Cargos (Peptide, SIRNA, mRNA, miRNA, Protein, Chemical, Others)
• Non-cargo

By Cell Source

• HEK293 Cells
• MSCs
• Platelets
• Erythrocytes
• Natural Killer Cells
• Others

By Application

• Therapeutics (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Infectious Diseases, Cosmetics, Others)
• Diagnostics

By End-user

• Health Care Providers
• Pharmaceutical & Biotechnology Companies
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Exosome Technologies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Exosome Technologies market include Aegle Therapeutics, Aruna Bio Inc., Bio-Techne Corporation, Carmine Therapeutics Inc., Codiak BioSciences Inc., Creative Biolabs, Danaher Corporation (Beckman Coulter Inc), Fujifilm Holdings Corporation, NOVADIP Biosciences S.A., OmniSpirant Limited, Thermo Fisher Scientific Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. EXOSOME TECHNOLOGIES - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Exosome Type
  • 3.7.2 Market Attractiveness Analysis By Cell Source
  • 3.7.3 Market Attractiveness Analysis By Application
  • 3.7.4 Market Attractiveness Analysis By End-user
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL EXOSOME TECHNOLOGIES MARKET ANALYSIS BY EXOSOME TYPE

• 5.1. Overview By Exosome Type
• 5.2. Historical and Forecast Data Analysis By Exosome Type
• 5.3. Loaded Cargos (Peptide, SIRNA, mRNA, miRNA, Protein, Chemical, Others) Historic and Forecast Sales By Regions
• 5.4. Non-cargo Historic and Forecast Sales By Regions

6. GLOBAL EXOSOME TECHNOLOGIES MARKET ANALYSIS BY CELL SOURCE

• 6.1. Overview By Cell Source
• 6.2. Historical and Forecast Data Analysis By Cell Source
• 6.3. HEK293 Cells Historic and Forecast Sales By Regions
• 6.4. MSCs Historic and Forecast Sales By Regions
• 6.5. Platelets Historic and Forecast Sales By Regions
• 6.6. Erythrocytes Historic and Forecast Sales By Regions
• 6.7. Natural Killer Cells Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL EXOSOME TECHNOLOGIES MARKET ANALYSIS BY APPLICATION

• 7.1. Overview By Application
• 7.2. Historical and Forecast Data Analysis By Application
• 7.3. Therapeutics (Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Infectious Diseases, Cosmetics, Others) Historic and Forecast Sales By Regions
• 7.4. Diagnostics Historic and Forecast Sales By Regions

8. GLOBAL EXOSOME TECHNOLOGIES MARKET ANALYSIS BY END-USER

• 8.1. Overview By End-user
• 8.2. Historical and Forecast Data Analysis By End-user
• 8.3. Health Care Providers Historic and Forecast Sales By Regions
• 8.4. Pharmaceutical & Biotechnology Companies Historic and Forecast Sales By Regions
• 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL EXOSOME TECHNOLOGIES MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE EXOSOME TECHNOLOGIES COMPANIES

• 10.1. Exosome Technologies Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF EXOSOME TECHNOLOGIES INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Aegle Therapeutics
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Aruna Bio Inc.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Bio-Techne Corporation
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Carmine Therapeutics Inc.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Codiak BioSciences Inc.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Creative Biolabs
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Danaher Corporation (Beckman Coulter Inc)
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Fujifilm Holdings Corporation
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. NOVADIP Biosciences S.A.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. OmniSpirant Limited
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Thermo Fisher Scientific Inc
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies